Kinnate Biopharma Past Earnings Performance
Past criteria checks 0/6
Kinnate Biopharma's earnings have been declining at an average annual rate of -36.4%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-36.4%
Earnings growth rate
7.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -70.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?
Jun 11
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
Jan 04FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor
Sep 21Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans
Sep 15Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03
Aug 11We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
May 15Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth
Jan 24We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth
Oct 09Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation
Jun 22We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate
Mar 03Kinnate Biopharma earns bulls as IPO quiet period ends
Dec 28Revenue & Expenses Breakdown
How Kinnate Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -113 | 28 | 91 |
| 30 Sep 23 | 0 | -127 | 30 | 103 |
| 30 Jun 23 | 0 | -127 | 31 | 102 |
| 31 Mar 23 | 0 | -122 | 31 | 95 |
| 31 Dec 22 | 0 | -116 | 30 | 88 |
| 30 Sep 22 | 0 | -111 | 30 | 82 |
| 30 Jun 22 | 0 | -105 | 28 | 78 |
| 31 Mar 22 | 0 | -99 | 26 | 74 |
| 31 Dec 21 | 0 | -90 | 23 | 67 |
| 30 Sep 21 | 0 | -77 | 18 | 60 |
| 30 Jun 21 | 0 | -63 | 14 | 49 |
| 31 Mar 21 | 0 | -49 | 11 | 39 |
| 31 Dec 20 | 0 | -36 | 7 | 29 |
| 30 Sep 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -10 | 3 | 9 |
Quality Earnings: KNTE is currently unprofitable.
Growing Profit Margin: KNTE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KNTE is unprofitable, and losses have increased over the past 5 years at a rate of 36.4% per year.
Accelerating Growth: Unable to compare KNTE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KNTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: KNTE has a negative Return on Equity (-70.7%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/03 11:28 |
| End of Day Share Price | 2024/04/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kinnate Biopharma Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Choi | Goldman Sachs |
| Roger Song | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |